Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nutex Health Inc. filings document the reporting obligations of a healthcare services and operations company with hospital, population health management and real estate-related activities. Recent Form 8-K reports furnish operating and financial results, including revenue, hospital division performance, earnings measures and cash flow, and disclose other corporate events tied to registration statements and auditor consents.
Proxy and annual-meeting filings cover board elections, advisory executive compensation votes, auditor ratification, common stock voting results and related governance disclosures. These documents also frame the company's capital actions, including common stock repurchase authorizations, within its public-company reporting record.
Nutex Health Inc. reported that director Kelvin Spears received 2,519 shares of common stock in a private, non-market transaction. The issuance relates to one-time obligations tied to his pro-rata share of an under-construction hospital transferred under a 2021 merger agreement, bringing his direct holdings to 34,656 shares.
Nutex Health Inc. director and CEO Thomas T. Vo reported an "other" Form 4 transaction involving 75,747 shares of common stock held indirectly through Micro Hospital Holdings LLC. The shares were issued in a private transaction to satisfy one-time obligations tied to two under-construction hospitals.
Following this restructuring-related issuance, Micro Hospital Holdings LLC is shown as holding 2,103,014 Nutex Health common shares indirectly for Vo, who owns and controls the LLC.
Nutex Health, Inc. ownership amendment reports that Pertento-related entities and Eduardo Marques each hold notable common stock positions. Pertento Partners LLP, Pertento Advisors LLC, and Eduardo Marques are listed with 405,029 shares (5.9%) each; Pertento Master Fund Limited holds 361,201 shares (5.3%). The filing is an amendment to a Schedule 13G/A with CUSIP 67079U306, dated 05/01/2026 and signed 05/07/2026.
Nutex Health Inc. reported higher profitability for the three months ended March 31, 2026. Total revenue rose 2.2% to $216.5 million, led by hospital division revenue of $207.6 million and modest growth in population health management. Hospital division visits increased 3.1% year over year to 49,742.
Net income attributable to Nutex Health climbed to $46.8 million, with diluted EPS of $6.52, up from $3.33 a year earlier. EBITDA was $68.3 million, while Adjusted EBITDA declined to $57.6 million from $72.8 million. Operating cash flow improved to $75.5 million, cash and cash equivalents reached $207.3 million, and long-term debt, net decreased to $24.3 million.
Nutex Health Inc. reported strong Q1 2026 results with higher profit and cash generation while continuing heavy use of arbitration under the No Surprises Act.
Total revenue was $216.5 million, up modestly from $211.8 million a year earlier, driven mainly by the hospital division’s $207.6 million. Net income rose to $62.8 million, with $46.8 million attributable to Nutex, more than double the prior-year $21.2 million. Basic earnings per share increased to $6.70, and operating income was $81.3 million.
Operating cash flow reached $75.5 million, lifting cash, cash equivalents and restricted cash to $210.6 million at March 31, 2026. The company spent $31.7 million on stock repurchases and retired 200,444 shares, while also settling certain disputes with former doctor owners and retiring additional shares.
Nutex’s business remains highly exposed to out-of-network reimbursement and arbitration. Arbitration-related costs for hospital and professional services were $46.1 million in the quarter, and accrued arbitration expenses increased to $56.8 million, reflecting the scale and complexity of the Independent Dispute Resolution process.
Nutex Health Inc. Schedule 13G filing shows BlackRock, Inc. reported beneficial ownership of 367,633 shares of Common Stock, representing 5.3% of the class as of 03/31/2026. The filing states BlackRock has sole voting power over 361,034 shares and sole dispositive power over 367,633 shares. The cover notes that these holdings reflect certain Reporting Business Units of BlackRock and do not include securities held by other BlackRock business units. The document is signed by a BlackRock Managing Director on 04/27/2026.
Reed Michael Lee reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Michael Lee received a grant of 823 Restricted Stock Units (RSUs) as equity compensation. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest 100% on April 23, 2027, with pro-rata vesting if he leaves the company without cause during the vesting period. Following this award, Lee holds a total of 1,426 RSUs directly. This filing reflects a compensation-related stock unit grant, not an open-market share purchase or sale.
Saunders Scott J reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Scott J. Saunders received a grant of 823 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Nutex common stock upon vesting. These RSUs vest 100% on April 23, 2027, and will vest on a pro-rata basis if he leaves the company without cause before that date. Following this award, Saunders holds a total of 1,426 RSUs directly.
Nutex Health Inc. director Frank E. Jaumot received a grant of 823 Restricted Stock Units (RSUs) on April 23, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of common stock upon vesting. These RSUs vest 100% on April 23, 2027, with pro‑rata vesting if he leaves the company without cause during the vesting period. Following this award, Jaumot holds 1,426 RSUs directly. This is a compensation-related acquisition, not an open‑market stock purchase or sale.
Grenas Cheryl Yvonne reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Cheryl Yvonne Grenas received a grant of 823 Restricted Stock Units (RSUs), each representing one share of common stock upon vesting. The RSUs vest 100% on April 23, 2027, with pro-rata vesting if she leaves the company without cause before that date. Following this award, she holds 1,426 RSUs directly.